ReviewAdvanced materials (Deerfield Beach, Fla.)2026
Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease.
Review in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence-driven design and optimization of mitochondria-targeted nanocarriers for chronic heart failure.Frontiers in bioengineering and biotechnology · 2026Review
- Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ischemic heart disease (IHD) remains the foremost cause of mortality worldwide, characterized by extensive myocardial injury following infarction with limited regenerative capacity of the adult mammalian heart. RNA interference (RNAi) nanotechnology is revolutionizing cardiac therapy by leveraging the sequence-oriented gene regulation that can overcome the obstacles hindering conventional therapeutic approaches. Here, we outline the evolving landscape of RNAi nanomedicine for cardiac repair, with an emphasis on therapeutic advances in myocardial infarction and atherosclerosis. We further discuss design considerations for constructing effective nanosystems, underscoring the critical principles by bridging mechanistic insights with material engineering. Finally, we delineate the translational pathway from bench to bedside, detailing current challenges and highlighting prospective opportunities for advancing RNAi therapeutics in cardiovascular therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.